Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.

Learn more about how we innovate to bring therapies to patients that significantly improve their lives.

About Us

Research

Research and development are at the heart of fulfilling Pfizer's purpose as we work to translate advanced science and technologies into the therapies that matter most.

Research

Our Products

Find out about our diversified health care portfolio which includes some of the world’s best-known prescription medicines and vaccines.

Our Products

Helping Communities

See how we support the people in the communities where we work and live through our community investment partnerships.

Helping Communities

SODIUM BICARBONATE INJECTION USP

Product Information

Prescribing Information (download PDF, 403KB)

Product Communication

June 30, 2017 Important Safety Information on Type I Recall Sodium Bicarbonate Inj 8.4% 50 mL vials - Risk of Infection Due to Potential Microbial Contamination (download PDF, 798KB)

June 23, 2017 NEWS REGARDING SODIUM BICARBONATE INJECTION 8.4% (download PDF, 798KB)

June 21, 2017 Second Notification (download PDF, 798KB)

June 20, 2017 Client Letter (download PDF, 798KB)

Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means. Please consult a qualified health professional for more detailed information.

Please contact Pfizer Canada Medical Information at 1 800 463-6001 with any comments or inquiries.

If you encounter technical difficulties in viewing our product information please contact Pfizer.ca

Français

Header menu

Search form

SODIUM BICARBONATE INJECTION USP

Product Information

Product Communication

Header menu

Search form

You are here

SODIUM BICARBONATE INJECTION USP

Product Information

Product Communication